Cedric Bogaert

Cedric Bogaert

Company: MyNeo

Job title: Co-Founder & Chief Executive Officer


What Makes Neoantigen-specific T-Cells Clinically Relevant & How to Clinically Exploit Neoantigens 12:15 pm

Immunotherapeutic manipulation of the antitumour immune response offers an attractive strategy to target genomic instability in cancer. Accurately determining the association of neoantigen immunogenicity with response to immune checkpoint inhibition relies on accurate prioritisation of immunogenic neoantigens. The workshop will cover: Emerging approaches for identifying, prioritising, and immunologically targeting personalised neoantigens Navigating how several major…Read more

day: Workshop Day

A Hanson Wade Group Company

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.